Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

9.470 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?

June 24, 2026

Over the past six months, Ocular Therapeutix’s shares (currently trading at $10.37) have posted a disappointing 18.5% loss, well below the S&P 500’s 7.8% gai...

Via StockStory

Topics Stocks

Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos

June 18, 2026

Check out the companies making headlines yesterday: Nubank (NYSE:NU): Digital banking platform Nubank (NYSE:NU) rose by 3.2% on Wednesday after the company r...

Via StockStory

Topics Economy

Why Ocular Therapeutix (OCUL) Stock Is Up Today

June 17, 2026

What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) jumped 7.2% in the afternoon session after the company anno...

Via StockStory

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 15, 2026

Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs.

Via The Motley Fool

Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips ↗

May 05, 2026

Via Chartmill

3 of Wall Street’s Favorite Stocks That Concern Us

June 10, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

1 Russell 2000 Stock to Research Further and 2 Facing Headwinds

May 28, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗

May 26, 2026

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.

Via The Motley Fool

Topics Regulatory Compliance Stocks

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.

Via The Motley Fool

Topics Regulatory Compliance

Why Ocular Therapeutix (OCUL) Stock Is Nosediving

May 05, 2026

What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 5.8% in the afternoon session after the company report...

Via StockStory

Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

May 05, 2026

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year...

Via StockStory

Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect

May 03, 2026

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to loo...

Via StockStory

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

April 02, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou...

Via StockStory

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

Via The Motley Fool

Topics Regulatory Compliance

1 Cash-Heavy Stock to Research Further and 2 We Brush Off

March 18, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

3 Reasons to Avoid OCUL and 1 Stock to Buy Instead

March 17, 2026

Shareholders of Ocular Therapeutix would probably like to forget the past six months even happened. The stock dropped 29.1% and now trades at $8.62. This was...

Via StockStory

3 Stocks Under $10 We Think Twice About

March 16, 2026

Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying busi...

Via StockStory

Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

March 11, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Small-Cap Stocks We’re Skeptical Of

March 05, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

3 of Wall Street’s Favorite Stocks We’re Skeptical Of

March 04, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why

February 27, 2026

Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about...

Via StockStory

Topics Economy Stocks

1 Russell 2000 Stock Worth Investigating and 2 We Avoid

February 26, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

1 Volatile Stock for Long-Term Investors and 2 Facing Challenges

February 18, 2026

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Via StockStory

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

February 17, 2026

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

February 17, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗

February 17, 2026

Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds ↗

February 16, 2026

Wall Street has grown increasingly optimistic ahead of the readout, with analysts pointing to a potential blockbuster opportunity in wet AMD.

Via Stocktwits

Wondering what's happening in today's after-hours session? ↗

February 16, 2026

Via Chartmill

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

February 16, 2026

In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly...

Via MarketMinute

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.